What data or evidence do we need to get these discoveries from bench to bedside faster, while prioritizing safety, efficacy, and effectiveness? - Alexa Woodward, PhD, Senior Director of Strategic Accounts at HealthVerity Nearly every major manufacturer is investing in obesity pipelines, including combination therapies that target multiple pathways
however, this link and the possible related immune effects are less studied about SGLT2i (Sodium-glucose co-transport 2 inhibitors) and GLP1-RAs (Glucagon-like peptide-1 receptor agonists)
CY: Writing-review & editing, Supervision, Resources, Funding acquisition, Conceptualization
doi: 10.1016/j.brainres.2019.146562
It is available as pure L-carnitine in crystalline form